|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
126,890,000 |
Market
Cap: |
1.15(B) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$9.05 - $9.1 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile CTI BioPharma is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies for blood-related cancers where there is an unmet medical need. Co. has one commercially approved product, VONJO (pacritinib), which has received approval in the U.S. by the U.S. Food and Drug Administration for the treatment of adult patients with intermediate or primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis with a platelet count below 50 x 10^9/L.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
5,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$27,500 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
9,850,628 |
Total Sell Value |
$0 |
$0 |
$0 |
$60,226,858 |
Total People Sold |
0 |
0 |
0 |
5 |
Total Sell Transactions |
0 |
0 |
0 |
26 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Seeley Bruce J. |
EVP, Chief Commercial Officer |
|
2016-12-31 |
4 |
A |
$0.30 |
$1,523 |
D/D |
5,000 |
310,000 |
|
- |
|
Seeley Bruce J. |
EVP, Chief Commercial Officer |
|
2016-06-30 |
4 |
A |
$0.29 |
$1,445 |
D/D |
5,000 |
305,000 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-06-24 |
4 |
AS |
$0.37 |
$3,654 |
D/D |
(10,000) |
1,780,133 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-05-27 |
4 |
AS |
$0.45 |
$4,471 |
D/D |
(10,000) |
1,790,133 |
|
- |
|
Mundinger Mary Oneil |
Director |
|
2016-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,695 |
360,019 |
|
- |
|
Love Richard L |
Director |
|
2016-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,695 |
535,824 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-04-29 |
4 |
AS |
$0.52 |
$5,162 |
D/D |
(10,000) |
1,800,133 |
|
- |
|
Tuckson Reed Vaughn |
Director |
|
2016-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,695 |
576,881 |
|
- |
|
Telling Fred |
Director |
|
2016-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
63,695 |
441,389 |
|
- |
|
Nudelman Phillip M Phd |
Director |
|
2016-04-29 |
4 |
OE |
$0.00 |
$0 |
D/D |
79,618 |
334,311 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-03-28 |
4 |
AS |
$0.49 |
$4,941 |
D/D |
(10,000) |
1,810,133 |
|
- |
|
Plunkett Matthew |
EVP, Chief Business Officer |
|
2016-03-21 |
4 |
D |
$0.55 |
$35,016 |
D/D |
(63,874) |
526,210 |
|
- |
|
Bianco Louis A |
EVP, Finance & Administration |
|
2016-03-21 |
4 |
D |
$0.55 |
$25,522 |
D/D |
(46,556) |
622,933 |
|
- |
|
Singer Jack W |
EVP, Chief Scientific Officer |
|
2016-03-21 |
4 |
D |
$0.55 |
$25,182 |
D/D |
(45,935) |
994,057 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-03-21 |
4 |
AS |
$0.55 |
$174,866 |
D/D |
(318,169) |
1,820,133 |
|
- |
|
Plunkett Matthew |
EVP, Chief Business Officer |
|
2016-03-04 |
4 |
AS |
$0.59 |
$5,904 |
D/D |
(10,000) |
590,084 |
|
- |
|
Singer Jack W |
EVP, Chief Scientific Officer |
|
2016-02-26 |
4 |
AS |
$0.62 |
$9,517 |
D/D |
(15,000) |
1,039,992 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-02-26 |
4 |
AS |
$0.63 |
$6,294 |
D/D |
(10,000) |
2,138,302 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-02-16 |
4 |
AS |
$0.42 |
$41,920 |
D/D |
(100,000) |
2,148,302 |
|
- |
|
Plunkett Matthew |
EVP, Chief Business Officer |
|
2016-02-04 |
4 |
AS |
$1.14 |
$11,539 |
D/D |
(10,000) |
600,084 |
|
- |
|
Bianco James A |
President and CEO |
|
2016-01-29 |
4 |
AS |
$1.20 |
$12,012 |
D/D |
(10,000) |
2,248,302 |
|
- |
|
Singer Jack W |
EVP, Chief Scientific Officer |
|
2016-01-29 |
4 |
AS |
$1.17 |
$17,730 |
D/D |
(15,000) |
1,054,992 |
|
- |
|
Lampert Mark N |
10% Owner |
|
2016-01-08 |
4 |
B |
$1.22 |
$71,338 |
I/I |
58,613 |
17,263,200 |
1.5 |
- |
|
Lampert Mark N |
10% Owner |
|
2016-01-08 |
4 |
B |
$1.22 |
$376,004 |
D/D |
308,934 |
3,090,744 |
2.45 |
- |
|
Lampert Mark N |
10% Owner |
|
2016-01-07 |
4 |
B |
$1.22 |
$9,848 |
I/I |
8,091 |
17,204,587 |
1.5 |
- |
|
229 Records found
|
|
Page 5 of 10 |
|
|